1487 related items for PubMed ID: 18789766
1. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[Abstract] [Full Text] [Related]
2. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[Abstract] [Full Text] [Related]
3. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[Abstract] [Full Text] [Related]
4. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[Abstract] [Full Text] [Related]
5. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators.
Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650
[Abstract] [Full Text] [Related]
6. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
[Abstract] [Full Text] [Related]
7. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.
Lancet; 2011 Nov 19; 378(9805):1779-87. PubMed ID: 22047971
[Abstract] [Full Text] [Related]
8.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
9. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.
Cochrane Database Syst Rev; 2013 Jun 06; (6):CD008933. PubMed ID: 23744561
[Abstract] [Full Text] [Related]
10. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
Lancet Neurol; 2010 Jul 06; 9(7):672-80. PubMed ID: 20542736
[Abstract] [Full Text] [Related]
11.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 06; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
14. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators.
Lancet Neurol; 2011 Aug 06; 10(8):691-701. PubMed ID: 21742556
[Abstract] [Full Text] [Related]
15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
Lancet Neurol; 2011 Jun 06; 10(6):520-9. PubMed ID: 21571593
[Abstract] [Full Text] [Related]
16. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, PreCISe study group.
Lancet; 2009 Oct 31; 374(9700):1503-11. PubMed ID: 19815268
[Abstract] [Full Text] [Related]
17. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G, Filippi M, Wolinsky JS.
Ann Neurol; 2001 Mar 31; 49(3):290-7. PubMed ID: 11261502
[Abstract] [Full Text] [Related]
18. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
[Abstract] [Full Text] [Related]
19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
20. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
Lancet Neurol; 2011 Apr 26; 10(4):338-48. PubMed ID: 21397567
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
